Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 2, 2013, Pages

  Phillips, Elizabeth ^a,b,c,d   Bartlett, John A ^e   Sanne, Ian ^f   Lederman, Michael M ^g   Hinkle, John ^h   Rousseau, Franck ⁱ   Dunn, David ^a   Pavlos, Rebecca ^a   James, Ian ^a   Mallal, Simon A ^a,b   Haas, David W ^j  

^a MURDOCH UNIVERSITY   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h EarlyPhase Sciences Inc   (United States)

ⁱ Tranzyme Pharma   (United States)

^j VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; HLA B ANTIGEN; HLA DRB1 ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ALLELE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS; HUMAN; HYPERSENSITIVITY; LETTER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPARTATE AMINOTRANSFERASES; DOUBLE-BLIND METHOD; DRUG-INDUCED LIVER INJURY; FEMALE; GENOTYPE; HIV INFECTIONS; HLA-B ANTIGENS; HLA-DRB1 CHAINS; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEVIRAPINE; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; SOUTH AFRICA;

EID: 84872833727     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827ca50f     Document Type: Letter

References (10)

1. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19:97-99. (Pubitemid 40111026)
2. Littera R, Carcassi C, Masala A, et al. HLAdependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS. 2006;20: 1621-1626. (Pubitemid 44162404)
3. Gatanaga H, Yazaki H, Tanuma J, et al. HLACw8 primarily associated with hypersensitivity to nevirapine. AIDS. 2007;21:264-265. (Pubitemid 46036947)
4. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics. 2009;19: 139-146.
5. Phillips E, Keane N, Blyth C, et al. Both HLA class I restricted CD8+ and class I restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. Proceedings of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011. Abstract H1-1399c.
6. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS. 2011;25:1271-1280.
7. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43:783-786. (Pubitemid 44330746)
8. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825-829. (Pubitemid 40349795)
9. Mallal S, Nolan D, Witt C, et al. Association between the presence of HLA-B*5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727-732. (Pubitemid 34215071)
10. Hung SI, Chung WH, Liou LB, et al. HLAB* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102: 4134-4139.